$Acrivon Therapeutics(ACRV.US)$Acrivon Therapeutics: Acr-2316, a Potential First-in-Class Dual Wee1/Pkmyt1 Inhibitor, Ind Timeline Accelerated With Filing Now Expected in Q3 2024
$Acrivon Therapeutics(ACRV.US)$ NEWS Acrivon Therapeutics to Host Corporate R&D Event Highlighting AP3 and Pipeline Progress, Including Ongoing Prospective Validation of ACR-368 OncoSignature with Initial Phase 2 Data for ACR-368, and Preclinical Progress for ACR-2316 WATERTOWN, Mass., April 16, 2024 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matche...
$Acrivon Therapeutics(ACRV.US)$ NEWS Acrivon Therapeutics Presents Data at AACR Annual Meeting Highlighting the Capabilities of Acrivon Predictive Precision Proteomics (AP3) for the Discovery of ACR-2316, a Novel, Selective WEE1/PKMYT1 Inhibitor, and the Identification of Actionable Resistance Mechanisms to ACR-368 Acrivon Therapeutics, Inc. announced data from two posters presented at the AACR Annual Meeting. ACR-2316, a dual WEE1/PKMYT1 inhibitor, showed potent anticancer activity in preclin...
Acrivon Therapeutics Secures $130 Million in Private Placement Financing: A Leap Forward in Cancer Treatment Innovation. In an era where the battle against cancer continues to demand innovative solutions, Acrivon Therapeutics has taken a significant step forward by securing $130 million through private placement financing. This move not only underscores the biotech industry's confidence in Acrivon's pote...
JESSE JAMES8832 : 我期望這樣做得更好
JESSE JAMES8832 : 也許填補這個空隙到 6.62?
Trytosaveabit樓主 JESSE JAMES8832: 是啊!但是看看 PCSA!它只是獲得 PT 增加和飛行!這會帶來好消息和 PT 的增加和混亂嗎?嘿河
Trytosaveabit樓主 JESSE JAMES8832: 它可能會嘗試嗎?